Look back at pharma news in week to September 28

Last week’s top news stories including some positive and exciting new research data, including Amarin's trial of Vascepa in cardiovascular outcomes that beat expectations am sent the firm’s shares rocketing. There were also strong results for Roche’s immuno-oncology drug Tecentriq in a small population of small cell lung cancer patients, and Takeda’s successful trial of Alunbrig in lung cancer. On the regulatory front, AstraZeneca’s lung cancer drug Imfinzi gained European approval, adding to competition in the sector, while Verastem gained US Food and Drug Administration clearance for its blood cancer drug Copiktra, but with a Black Box warning.

Amarin lands the catch of a lifetime

Top-line result from  Amarin’s REDUCE-IT trial has smashed expectations, delighting shareholders and framing Vascepa as a potentially practice-changing product, comments Amy Brown on Vantage, the editorial arm of the Evaluate group.